| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
09-01-2009, 04:51 PM
|
#11 | ||
|
|||
|
In Remembrance
|
More from LindaH in pipeline email:
More on the Pimavanserin "failed " trial in Acadia press release., 9/1/09 seee ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis full text at http://www.fiercebiotech.com/press-releases/acadia-pharmaceuticals-announces-results-phase-iii-trial-pimavanserin-parkinsons-dise?utm_medium=nl&utm_source=internal Excerpts - bold is me and by the way, no one wants these trials to be successful more than patients do. Patients received [2 different - 10 mg and 40 mg] oral doses of either pimavanserin or placebo once daily for six weeks. [time enough to work thru placebo?but....but..... doesn't it last for years?] The primary endpoint was antipsychotic efficacy as measured using hallucinations and delusions domains of the SAPS. The key secondary endpoint was motoric tolerability as measured using Parts II and III of the UPDRS." Patients showed marked improvements in the SAPS scores across all study arms. Mean reductions in SAPS scores were 5.9 points in the placebo arm, 5.8 points in the 10 mg pimavanserin arm, and 6.7 points in the 40 mg pimavanserin arm. Statistical significance was not achieved in either pimavanserin arm primarily due to the larger than expected improvement in placebo-treated patients... Good news? Meanwhile, we are continuing with the second Phase III PDP trial with pimavanserin. paula
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Open Source Drug Development | Parkinson's Disease | |||
6 weeks?
Linear Mode
